GlassScriptPhysician profile
Cesar Cruz
NPI 1861766099
$6,454.93
in general payments reported to CMS, 2019-2025
24 companies · $24.78 in 2025
The $24.78 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,353 · 2020: $646 · 2021: $2,099 · 2022: $1,310 · 2023: $954 · 2024: $68.25 · 2025: $24.78.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,047.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,047.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,475.51 | 2019-2024 | Invega Sustenna, Spravato, Xarelto |
| Sunovion Pharmaceuticals INC. | $1,158.39 | 2019-2022 | |
| Abbvie INC. | $972.86 | 2021-2023 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $712.56 | 2019-2025 | Uzedy, Austedo Xr |
| Alkermes, INC. | $397.24 | 2019-2023 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $279.73 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $217.70 | 2019-2024 | Ingrezza |
| Indivior INC. | $191.30 | 2019-2023 | Perseris |
| Lundbeck LLC | $180.55 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $148.27 | 2021-2023 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $143.23 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $137.06 | 2020-2023 | |
| Allergan, INC. | $95.90 | 2019-2020 | |
| Neuronetics, INC. | $68.48 | 2022 | |
| Eisai INC. | $55.50 | 2020-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $33.29 | 2022-2023 | Quviviq |
| Adlon Therapeutics L.P. | $32.95 | 2021 | |
| Bioxcel Therapeutics, INC. | $28.12 | 2023 | Igalmi |
| Axsome Therapeutics, INC. | $25.99 | 2023 | Auvelity |
| Avanir Pharmaceuticals, INC. | $21.83 | 2019 | |
| Noven Therapeutics, LLC | $20.62 | 2022 | |
| Noven Pharmaceuticals, INC. | $20.43 | 2020 | |
| Sun Pharmaceutical Industries INC. | $20.20 | 2021 | |
| Bausch Health US, LLC | $17.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cesar Cruz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.